Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Current Medicinal Chemistry
|
November 11, 2008
Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice
P Igaz, Z Tömböl, P M Szabó, et al.
Cell Biology International
|
April 25, 2000
Interleukin-6-induced production of type II acute phase proteins and expression of junB gene are downregulated by human recombinant growth hormone in vitro
B Derfalvi, P Igaz, K A Fulop, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
May 8, 2001
Bidirectional communication between histamine and cytokines
P Igaz, I Novák, E Lázaár, et al.
Clinical Genetics
|
April 16, 2003
Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer
A Patócs, Z Valkusz, P Igaz, et al.
Orvosi Hetilap
|
January 27, 2000
[Effective demeclocycline therapy in a patient with over-secretion of antidiuretic hormone following head trauma]
P Igaz, M Tóth, M Mezödy, et al.
Cytokine
|
September 2, 1998
Soluble interleukin 6 (IL-6) receptor influences the expression of the protooncogene junB and the production of fibrinogen in the HepG2 human hepatoma cell line and primary rat hepatocytes
P Igaz, S Tóth, S Rose-John, et al.
Journal of Endocrinological Investigation
|
July 2, 2013
In silico analysis of pathways affected by differentially expressed microRNA in adrenocortical tumors
A Zsippai, P M Szabó, D R Szabó, et al.
Medical Hypotheses
|
January 24, 2017
MEN1 and microRNAs: The link between sporadic pituitary, parathyroid and adrenocortical tumors?
Z Nagy, P M Szabó, V K Grolmusz, et al.
Orvosi Hetilap
|
March 26, 1999
[Ret-protooncogene mutation, verified by molecular genetic methods, in a Hungarian MEN Type 2a family]
P Igaz, K Rácz, M Tóth, et al.
Immunology Letters
|
March 21, 2000
Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production
P Igaz, A Horváth, B Horváth, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Current Medicinal Chemistry
|
November 11, 2008
Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice
P Igaz, Z Tömböl, P M Szabó, et al.
Cell Biology International
|
April 25, 2000
Interleukin-6-induced production of type II acute phase proteins and expression of junB gene are downregulated by human recombinant growth hormone in vitro
B Derfalvi, P Igaz, K A Fulop, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]
|
May 8, 2001
Bidirectional communication between histamine and cytokines
P Igaz, I Novák, E Lázaár, et al.
Clinical Genetics
|
April 16, 2003
Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer
A Patócs, Z Valkusz, P Igaz, et al.
Orvosi Hetilap
|
January 27, 2000
[Effective demeclocycline therapy in a patient with over-secretion of antidiuretic hormone following head trauma]
P Igaz, M Tóth, M Mezödy, et al.
Cytokine
|
September 2, 1998
Soluble interleukin 6 (IL-6) receptor influences the expression of the protooncogene junB and the production of fibrinogen in the HepG2 human hepatoma cell line and primary rat hepatocytes
P Igaz, S Tóth, S Rose-John, et al.
Journal of Endocrinological Investigation
|
July 2, 2013
In silico analysis of pathways affected by differentially expressed microRNA in adrenocortical tumors
A Zsippai, P M Szabó, D R Szabó, et al.
Medical Hypotheses
|
January 24, 2017
MEN1 and microRNAs: The link between sporadic pituitary, parathyroid and adrenocortical tumors?
Z Nagy, P M Szabó, V K Grolmusz, et al.
Orvosi Hetilap
|
March 26, 1999
[Ret-protooncogene mutation, verified by molecular genetic methods, in a Hungarian MEN Type 2a family]
P Igaz, K Rácz, M Tóth, et al.
Immunology Letters
|
March 21, 2000
Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production
P Igaz, A Horváth, B Horváth, et al.
Page
of 4